Chair, Radiation Oncology, University of Vermont Health
Burlington, VT
Joined January 2014
- Tweets7K
- Following1.4K
- Followers4.6K
- Likes42.2K
Honored to be elected to the @nnecos_oncology Board. NNECOS brings together oncology across ME, NH, and VT & gives our trainees a real regional stage. Looking forward to the work ahead with colleagues across the region.
2026 NNECOS BOD Election Results
Thanks to all who participated in the 2026 NNECOS Board of Directors Election, as candidates and as voters. We are pleased to announce the following individuals have been elected/reelected to a three year term on the board, which begins January 1.
ALT Headshots of three newly elected 2026 NNECOS Board members against a blue background with election results banner.
ALT Headshots of four reelected 2026 NNECOS Board members against a blue background.
ENZARAD @JCO | ANZUP 1303
n=802 | mFU 92 mo
ADT+RT ± enza 24 mo vs NSAA 6 mo
MFS/OS overall ⛔️
pelvic RT subgroup 🎯 HR 0.47
no Decipher/PAM50 - still unclear who benefits from intensification
ascopubs.org/doi/10.1200/JCO…
#ESMO26 @niazi_Dr7 DASL-HiCaP (ANZUP1801)
n=1,106 | mFU 3.8 yrs | 85% definitive RT
darolutamide + ADT + RT v placebo + ADT + RT
MFS-CI ➡️ HR 0.42 (0.27–0.66)
4-yr MFS 95% vs 88%
🚨📣📣 #ESMO26 presidential: @niazi_Dr7 Adding darolutamide to ADT + RT dramatically ⬇️ risk of metastasis or death in high-risk localized prostate cancer. Phase 3 DASL-HiCaP = 58% ⬇️ in MFS (HR 0.42) + early OS signal (HR 0.88). #ProstateCancer #RadOnc #pcsm @ChrisSweens1
Nat Lester-Coll, MD retweeted
At #ASTRO26, we are proud to welcome so many Yale attendees, including our current residents and the alumni of our Radiation Oncology Residency Program @YaleRadOnc, all representing @YaleMed @SmilowCancer @YNHH and advancing the field of radiation oncology. @ASTRO_org @OncoAlert
Nat Lester-Coll, MD retweeted
Back in 🇬🇧 but still able to listen to @nickva1 presenting @ASTRO_org #ASTRO26 @royalmarsdenNHS @EmmaHall71 No surprises here, patients have better sexual outcomes after SBRT compared to prostatectomy
Grateful to organizers for PRO 11 @ #ASTRO26:
Trial design keeps getting more complicated. Ph II data, de-escalation/omission studies, new tech routinely reported as practice-changing.
Outstanding talks on how to read that evidence and which results should change practice!
#ASTRO26 climate change, IT risk, and other system shocks make this more relevant every year. The real value here was in the stories: lessons for prevention and prep, and what we can actually do to safeguard RT when the next disruption hits.
Thank you to this panel!
This Sunday!
WHEN DISASTER STRIKES
⛈️ 🌬️ 🌀 🔥
Safeguarding Radiotherapy's Value and Continuity Across Catastrophic Events
#ASTRO26 Annual Meeting
Educational Session 8244
📆 Sunday 9/27/2026
⏰ 2:30 PM - 4:00 PM
📍 Room 257
Excited to see you at this session.
Nat Lester-Coll, MD retweeted
Long-term PACE-A data at #ASTRO26 (van As LBA32, Yasar LBA10): the first randomized comparison of prostatectomy vs SBRT, 36.25 Gy in 5 fractions.
These are contemporary surgical data: all prostatectomies were laparoscopic, 84% robotic.
Using ≥1 pad/day, RP vs SBRT:
• 2 years: 50% vs 7%
• 5 years: 48% vs 8%
Sexual function at 5 years:
• EPIC sexual domain: 62→17 after RP vs 79→58 after SBRT
• Median IIEF-5: 5 vs 19
Important caveats: as-treated analysis, approximately 60% PRO completion at 5 years, baseline sexual function imbalance, and enrollment of 123 of a planned 234 patients.
Biochemical control looks similar through 8 years, but 13 events cannot establish equivalence.
For shared decision-making, these are numbers I’d want patients to see. Every patient considering prostatectomy should have the opportunity to meet with a radiation oncologist before choosing treatment.
#RadOnc #PCSM
#ASTRO26 A071801
1-4 BMs
SRS (12-20Gy by volume) or fSRS (27Gy/3 <30cc or 30Gy/5 >30cc) after resection
fSRS ➡️ superior surgical bed control
no differences in RN or QoL
Nat Lester-Coll, MD retweeted
I’ve been saying this for years…
Now we have randomized data.
GETUG P05: brachytherapy boost vs dose-escalated EBRT in intermediate-risk prostate cancer.
Oncologic outcomes similar but far more toxicity with brachy.
#ASTRO26 #ProstateCancer
@ASTRO_org @NehaVapiwala @AmarUKishan @DrAndrewLoblaw @seanmmcbride @HimanshuNagarMD @TylerSbrt @seanmmcbride @alison_tree @Soum_Roy_RadOnc @NicholasZaorsky @angela_jia_
Nat Lester-Coll, MD retweeted
Boston-bound for #ASTRO26 — “When Disaster Strikes” is feeling particularly timely. Join us Sunday for a conversation on safeguarding radiotherapy continuity through catastrophic events @fumikochino @MDAnderson_ES @DrNogueiraL @AmericanCancer @DartmouthCancer @SpeedofLightFdn
Nat Lester-Coll, MD retweeted
Radiotherapy after surgery halves risk of recurrence in a type of brain tumour that can often grow back, trial shows.
Find out more in The Lancet: spkl.io/60137TUFS #EANO2026
ALT Kaplan\u2013Meier estimates of disease-free survival by treatment group in the intention-to-treat population. Median follow-up was 64 months (IQR 50\u201375). HR=hazard ratio. Copyright: 2026 The Author(s). Published by Elsevier Ltd. CC BY 4.0.
Nat Lester-Coll, MD retweeted
Happening in 2 wks! Join us Sun 9/27, 4:45P #ASTRO26:
Making Sense of Trials in Community Rad Onc: From Headlines to High-Value Care
3 talks on Ph II trials, omission studies & novel RT technologies - practical frameworks for interpreting new data & translating into practice.
Nat Lester-Coll, MD retweeted
Landmark, practice changing study at #WCLC26. The phase III MAVERICK study shows no improvement in OS with PCI for SCLC, across limited and extensive stages, with worse cognitive failure free survival and increased toxicity in PCI arm.
The end of the PCI era.
Nat Lester-Coll, MD retweeted
📊 Research Summary: In localized intermediate-risk #ProstateCancer, stereotactic body #Radiotherapy and moderately hypofractionated intensity-modulated radiation therapy had similar urinary quality-of-life outcomes, while bowel outcomes favored stereotactic body radiotherapy.
ja.ma/4fSjyDM
